3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Carcinoma, Neuroendocrine
1
Carcinoid Tumor
1
Interventions
Everolimus
9
Cisplatin
8
Temozolomide
6
Nivolumab
5
Etoposide
5
Carboplatin
5
Bevacizumab
5
lutetium Lu 177 dotatate
4
Capecitabine
4
pembrolizumab
3
Irinotecan
3
sintilimab
2
dostarlimab
2
cabozantinib
2
azaspirane
2
avelumab
2
atezolizumab
2
Paclitaxel
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Ipilimumab
2
Immunoglobulin G
2
IFL protocol
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Disulfides
2
zimberelimab
1
surufatinib
1
selinexor
1
pertuzumab
1
pasireotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Neuroendocrine
×
177Lu-octreotate
×
Clear all
NCT02754297
2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2
Active not recruiting
275 enrolled